Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company, announced it has received a Diamond Pinnacle Award for AI Innovation in the Clinical Decision AI category. The award recognizes the company's use of augmented intelligence in its Nociscan solution for chronic low back pain, one of healthcare's most pervasive and costly challenges. This recognition follows Aclarion's earlier selection as a 2025 Digital Health Awards at HLTH winner, where Nociscan was honored for its potential to transform the evaluation and management of discogenic low back pain.
Chronic low back pain affects approximately 266 million people worldwide, making it a global healthcare problem with significant economic impact. Aclarion's Nociscan platform is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. The technology uses MR spectroscopy to identify chemical biomarkers within intervertebral discs, which are then processed through proprietary algorithms that classify whether a disc's biochemical profile is consistent with a painful or nonpainful disc. Physicians use this information alongside imaging, clinical evaluation, and their own expertise to optimize treatment planning for patients with discogenic low back pain.
Brent Ness, CEO of Aclarion, stated, "Receiving recognition from both the Pinnacle Awards and HLTH underscores the accelerating momentum behind our technology. Chronic low back pain remains one of the most challenging and costly conditions in medicine. Providing physicians with objective biochemical data has the potential to fundamentally improve how discogenic pain is evaluated and treated." The company continues to expand adoption of Nociscan among spine specialists seeking more objective tools for evaluating chronic low back pain. Since Nociscan is delivered through a cloud-based analytics platform, it can be rapidly deployed across imaging centers and health systems without requiring new hardware infrastructure.
When used alongside other diagnostic tools, clinical data demonstrates a 97% surgical success rate when all Nociscan-positive discs are treated. The Pinnacle and HLTH awards reflect growing external validation of Aclarion's mission to bring objective, MR spectroscopy-based biomarker analysis into routine clinical decision-making while advancing a new model of MedTech innovation built on scalable, cloud-based algorithms. For more information about Aclarion and Nociscan, visit www.aclarion.com.
